JP7459094B2 - ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 - Google Patents

ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 Download PDF

Info

Publication number
JP7459094B2
JP7459094B2 JP2021530299A JP2021530299A JP7459094B2 JP 7459094 B2 JP7459094 B2 JP 7459094B2 JP 2021530299 A JP2021530299 A JP 2021530299A JP 2021530299 A JP2021530299 A JP 2021530299A JP 7459094 B2 JP7459094 B2 JP 7459094B2
Authority
JP
Japan
Prior art keywords
mmol
compound
amino
pyrazol
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510925A5 (https=
JP2022510925A (ja
JPWO2020119819A5 (https=
Inventor
ワン，ジャオクイ
ローレンス バスケス，マイケル
リー，シアオドン
Original Assignee
リンク ファーマシューティカルズ シーオー．エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンク ファーマシューティカルズ シーオー．エルティーディー． filed Critical リンク ファーマシューティカルズ シーオー．エルティーディー．
Publication of JP2022510925A publication Critical patent/JP2022510925A/ja
Publication of JP2022510925A5 publication Critical patent/JP2022510925A5/ja
Publication of JPWO2020119819A5 publication Critical patent/JPWO2020119819A5/ja
Priority to JP2024038370A priority Critical patent/JP7802106B2/ja
Priority to JP2024038369A priority patent/JP7802105B2/ja
Application granted granted Critical
Publication of JP7459094B2 publication Critical patent/JP7459094B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021530299A 2018-12-14 2019-12-16 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 Active JP7459094B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024038370A JP7802106B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP2024038369A JP7802105B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/121165 2018-12-14
PCT/CN2018/121165 WO2020118683A1 (en) 2018-12-14 2018-12-14 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PCT/CN2019/125552 WO2020119819A1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024038369A Division JP7802105B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP2024038370A Division JP7802106B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法

Publications (4)

Publication Number Publication Date
JP2022510925A JP2022510925A (ja) 2022-01-28
JP2022510925A5 JP2022510925A5 (https=) 2022-11-04
JPWO2020119819A5 JPWO2020119819A5 (https=) 2022-11-04
JP7459094B2 true JP7459094B2 (ja) 2024-04-01

Family

ID=71076270

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021530299A Active JP7459094B2 (ja) 2018-12-14 2019-12-16 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP2024038369A Active JP7802105B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP2024038370A Active JP7802106B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024038369A Active JP7802105B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP2024038370A Active JP7802106B2 (ja) 2018-12-14 2024-03-12 ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法

Country Status (14)

Country Link
US (6) US12421213B2 (https=)
EP (1) EP3877381A4 (https=)
JP (3) JP7459094B2 (https=)
KR (2) KR20250162926A (https=)
CN (7) CN119118999A (https=)
AU (3) AU2019399939B2 (https=)
BR (1) BR112021011147A2 (https=)
CA (3) CA3122872A1 (https=)
EA (1) EA202191188A1 (https=)
IL (3) IL314086A (https=)
MX (3) MX2021006866A (https=)
SG (1) SG11202105730TA (https=)
TW (3) TWI889397B (https=)
WO (2) WO2020118683A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
CN112661655B (zh) * 2020-12-29 2022-02-18 江苏云朴医药新材料科技有限公司 一种1-氨甲基-1-环丙醇类化合物及其合成方法
EP4577535A1 (en) * 2022-08-22 2025-07-02 Hangzhou Highlightll Pharmaceutical Co., Ltd. Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
CN115572269B (zh) * 2022-10-08 2024-05-17 广州大学 一种n-三氟异丙基唑类和吲哚化合物及其制备方法
WO2023151724A1 (zh) * 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116751191B (zh) * 2023-05-19 2025-09-16 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
WO2024239282A1 (zh) 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
TW202545932A (zh) * 2024-01-26 2025-12-01 大陸商凌科藥業(杭州)有限公司 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用
WO2025157231A1 (zh) * 2024-01-26 2025-07-31 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用
WO2025256636A1 (zh) * 2024-06-13 2025-12-18 凌科药业(杭州)有限公司 含氮化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
CN108864057A (zh) 2017-05-16 2018-11-23 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2616383C (en) 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US8481538B2 (en) * 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009064835A1 (en) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN103781780B (zh) * 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
KR101361149B1 (ko) * 2012-07-17 2014-02-24 전남대학교산학협력단 가뭄 스트레스 저항성 관련 유전자 및 형질전환 식물체
EP3080103B9 (en) * 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
CN108864057A (zh) 2017-05-16 2018-11-23 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
IL283968A (en) 2021-07-29
BR112021011147A2 (pt) 2021-08-31
AU2024201128A1 (en) 2024-03-14
JP2022510925A (ja) 2022-01-28
US20220298144A1 (en) 2022-09-22
AU2024201125B2 (en) 2025-03-06
MX2021006866A (es) 2021-11-17
WO2020119819A1 (en) 2020-06-18
CN118903141A (zh) 2024-11-08
TW202440559A (zh) 2024-10-16
KR20210125983A (ko) 2021-10-19
US20230416235A1 (en) 2023-12-28
IL314086A (en) 2024-09-01
AU2019399939B2 (en) 2024-07-11
JP2024089673A (ja) 2024-07-03
AU2024201125A1 (en) 2024-03-14
CN113227074A (zh) 2021-08-06
CN118290403A (zh) 2024-07-05
JP7802105B2 (ja) 2026-01-19
US12098142B2 (en) 2024-09-24
TW202440558A (zh) 2024-10-16
TW202039474A (zh) 2020-11-01
AU2024201128B2 (en) 2025-03-06
KR20250162926A (ko) 2025-11-19
US20240083881A1 (en) 2024-03-14
EP3877381A1 (en) 2021-09-15
US12030870B2 (en) 2024-07-09
CN113227074B (zh) 2024-08-16
MX2024005747A (es) 2024-05-28
EA202191188A1 (ru) 2021-11-29
CN118388457A (zh) 2024-07-26
MX2024005744A (es) 2024-05-28
EP3877381A4 (en) 2022-08-24
KR102881668B1 (ko) 2025-11-04
JP2024088646A (ja) 2024-07-02
CA3122872A1 (en) 2020-06-18
CN118955477A (zh) 2024-11-15
IL283968B2 (en) 2025-09-01
US20250115586A1 (en) 2025-04-10
US11981663B2 (en) 2024-05-14
SG11202105730TA (en) 2021-06-29
CN119118999A (zh) 2024-12-13
US12595253B2 (en) 2026-04-07
US20240025882A1 (en) 2024-01-25
TWI866940B (zh) 2024-12-21
CA3230060A1 (en) 2020-06-18
JP7802106B2 (ja) 2026-01-19
US12421213B2 (en) 2025-09-23
US20230002362A1 (en) 2023-01-05
TWI889397B (zh) 2025-07-01
CA3230071A1 (en) 2020-06-18
IL314084A (en) 2024-09-01
CN118903142A (zh) 2024-11-08
AU2019399939A1 (en) 2021-06-24
TWI889396B (zh) 2025-07-01
IL283968B1 (en) 2025-05-01
WO2020118683A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
JP7802106B2 (ja) ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
EA048017B1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
BR122024013977A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
HK40057223A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40057223B (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7459094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150